ArticleJournal of medical cases2025
Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation Successfully Treated With Daratumumab: Report of Two Cases.
Article in Journal of medical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pure red cell aplasia (PRCA) is a potential complication after ABO-incompatible allogeneic hematopoietic stem cell transplantation (HCT). In case where PRCA persists beyond 60 days post-HCT, spontaneous resolution is rare, and therapeutic intervention is typically required. However, there is currently no established standard of care for its management. We report two cases of post-transplant PRCA that were refractory to conventional therapies, including erythropoietin and rituximab, and were successfully treated with daratumumab. These cases underscore the potential role of daratumumab as an effective therapeutic option in the management of PRCA following ABO-incompatible HCT. Given the limited data available on its use in this setting, our report contributes with valuable clinical evidence supporting its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.